首页 > 最新文献

Clinical immunology最新文献

英文 中文
CD14+CD11c+HLA-II− monocytes are identified to be associated with osteoclastogenesis in ankylosing spondylitis CD14+CD11c+HLA-II−单核细胞与强直性脊柱炎的破骨细胞发生有关
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-08-18 DOI: 10.1016/j.clim.2025.110586
Lian Gui , Zena Chen , Liudan Tu , Liuzhong Zhou , Qiujing Wei , Jieruo Gu
Abnormal monocytes are involved in the pathogenesis of ankylosing spondylitis (AS). We investigated the association between an imbalance of monocyte subpopulations and bone destruction in AS. Compared to controls, AS patients exhibited increased CD14+CD11c+HLA-II monocytes and decreased CD14+CD11c+HLA-II+ monocytes in peripheral blood. LPS stimulation promoted a shift from CD14+CD11c+HLA-II monocytes toward CD14+CD11c+HLA-II+ monocytes, enhancing the former's capacity to promote CD4+ T cell proliferation. Micro RNA-seq analysis indicated that AS CD14+CD11c+HLA-II monocytes were involved in osteoclast differentiation and overproduced soluble osteoclastogenic cytokine CSF-1. In 40 AS patients, evaluated CD14+CD11c+HLA-II monocytes correlated positively with Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation score (r = 0.336, P = 0.034) and bone erosion score (r = 0.423, P = 0.007), but inversely with ankylosis score (r = −0.346, P = 0.029). Conversely, CD14+CD11c+HLA-II+ monocytes showed the opposite correlation. Our findings demonstrate that expansion of CD14+CD11c+HLA-II monocytes contribute to bone erosion in AS, potentially mediated through CSF-1-driven osteoclast differentiation.
异常单核细胞参与强直性脊柱炎(AS)的发病机制。我们研究了单核细胞亚群失衡与AS骨破坏之间的关系。与对照组相比,AS患者外周血中CD14+CD11c+HLA-II+单核细胞增加,CD14+CD11c+HLA-II+单核细胞减少。LPS刺激促进CD14+CD11c+HLA-II -单核细胞向CD14+CD11c+HLA-II+单核细胞的转变,增强了前者促进CD4+ T细胞增殖的能力。微RNA-seq分析表明,AS CD14+CD11c+HLA-II−单核细胞参与破骨细胞分化,并过量产生可溶性破骨细胞因子CSF-1。在40例AS患者中,CD14+CD11c+HLA-II -单核细胞与加拿大脊椎关节炎研究协会(SPARCC) MRI炎症评分(r = 0.336, P = 0.034)和骨侵蚀评分(r = 0.423, P = 0.007)呈正相关,与强直评分呈负相关(r = - 0.346, P = 0.029)。相反,CD14+CD11c+HLA-II+单核细胞表现出相反的相关性。我们的研究结果表明,CD14+CD11c+HLA-II -单核细胞的扩增有助于AS的骨侵蚀,可能通过csf -1驱动的破骨细胞分化介导。
{"title":"CD14+CD11c+HLA-II− monocytes are identified to be associated with osteoclastogenesis in ankylosing spondylitis","authors":"Lian Gui ,&nbsp;Zena Chen ,&nbsp;Liudan Tu ,&nbsp;Liuzhong Zhou ,&nbsp;Qiujing Wei ,&nbsp;Jieruo Gu","doi":"10.1016/j.clim.2025.110586","DOIUrl":"10.1016/j.clim.2025.110586","url":null,"abstract":"<div><div>Abnormal monocytes are involved in the pathogenesis of ankylosing spondylitis (AS). We investigated the association between an imbalance of monocyte subpopulations and bone destruction in AS. Compared to controls, AS patients exhibited increased CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>−</sup> monocytes and decreased CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>+</sup> monocytes in peripheral blood. LPS stimulation promoted a shift from CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>−</sup> monocytes toward CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>+</sup> monocytes, enhancing the former's capacity to promote CD4<sup>+</sup> T cell proliferation. Micro RNA-seq analysis indicated that AS CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>−</sup> monocytes were involved in osteoclast differentiation and overproduced soluble osteoclastogenic cytokine CSF-1. In 40 AS patients, evaluated CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>−</sup> monocytes correlated positively with Spondyloarthritis Research Consortium of Canada (SPARCC) MRI inflammation score (<em>r</em> = 0.336, <em>P</em> = 0.034) and bone erosion score (<em>r</em> = 0.423, <em>P</em> = 0.007), but inversely with ankylosis score (<em>r</em> = −0.346, <em>P</em> = 0.029). Conversely, CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>+</sup> monocytes showed the opposite correlation. Our findings demonstrate that expansion of CD14<sup>+</sup>CD11c<sup>+</sup>HLA-II<sup>−</sup> monocytes contribute to bone erosion in AS, potentially mediated through CSF-1-driven osteoclast differentiation.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"281 ","pages":"Article 110586"},"PeriodicalIF":3.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydrogen protects against autoimmune myocarditis by inhibiting necroptosis via the TNF/TNFR1 signalling pathway 氢通过TNF/TNFR1信号通路抑制坏死下垂,从而保护自身免疫性心肌炎
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-08-12 DOI: 10.1016/j.clim.2025.110577
Shuang Pan , Mengshu Yu , Bowei Fan , Bin Wang , Xinrui Yang , Jiawen Zhang , Xiaoqi Liu , Xiaojian Hong , Wei Yang
Autoimmune myocarditis refers to the inflammation of myocardial tissue caused by innate and adaptive immune responses, characterized by elevated levels of tumour necrosis factor-α (TNF-α), a classic pro-inflammatory factor. Although hydrogen exhibits anti-inflammatory and antioxidant properties, its therapeutic effects in autoimmune myocarditis have not been evaluated. Therefore, the present study aimed to explore whether hydrogen can alleviate autoimmune myocarditis via TNF-α. An experimental autoimmune myocarditis (EAM) model was established in BALB/c mice via subcutaneous injection of pig-derived myocardial myoglobin emulsified with complete Freund's adjuvant. The treatment group received 2 % hydrogen inhalation twice a day (3 h each time) for 21 days. CD4+ T cell expression was higher in the EAM group than in the Control group, and this increase was attenuated following treatment with hydrogen. Additionally, the levels of TNF-α and related inflammatory factors were substantially higher in the EAM group than in the Control group, and these changes were reversed following hydrogen treatment. Echocardiography assessments demonstrated a significant improvement in heart function following treatment with hydrogen compared to that in the EAM group. Pathological results revealed significant inflammatory cell infiltration and fibrosis in the hearts of the untreated EAM group. Tissue immunofluorescence and protein immunoblotting indicated elevated necroptosis markers in the EAM group, which were downregulated after treatment with hydrogen. This study demonstrates that hydrogen effectively ameliorated autoimmune myocarditis by modulating necroptosis via the TNF/TNFR1 signalling pathway, making it a promising novel therapeutic strategy for myocarditis.
自身免疫性心肌炎是指由先天和适应性免疫反应引起的心肌组织炎症,其特征是肿瘤坏死因子-α (TNF-α)水平升高,这是一种典型的促炎因子。虽然氢具有抗炎和抗氧化的特性,但其治疗自身免疫性心肌炎的效果尚未得到评价。因此,本研究旨在探讨氢是否能通过TNF-α缓解自身免疫性心肌炎。通过皮下注射经完全弗氏佐剂乳化的猪源性心肌肌红蛋白,建立了BALB/c小鼠实验性自身免疫性心肌炎(EAM)模型。治疗组给予2%氢气吸入,每日2次,每次3 h,连用21 d。EAM组CD4+ T细胞表达高于对照组,氢治疗后这种升高减弱。此外,EAM组的TNF-α和相关炎症因子水平明显高于对照组,这些变化在氢治疗后被逆转。超声心动图评估显示,与EAM组相比,氢治疗后心功能有显著改善。病理结果显示,EAM治疗组心脏有明显的炎症细胞浸润和纤维化。组织免疫荧光和蛋白质免疫印迹显示,EAM组坏死下垂标志物升高,氢治疗后下调。本研究表明,氢通过TNF/TNFR1信号通路调节坏死性下垂,有效改善自身免疫性心肌炎,使其成为治疗心肌炎的一种有前景的新策略。
{"title":"Hydrogen protects against autoimmune myocarditis by inhibiting necroptosis via the TNF/TNFR1 signalling pathway","authors":"Shuang Pan ,&nbsp;Mengshu Yu ,&nbsp;Bowei Fan ,&nbsp;Bin Wang ,&nbsp;Xinrui Yang ,&nbsp;Jiawen Zhang ,&nbsp;Xiaoqi Liu ,&nbsp;Xiaojian Hong ,&nbsp;Wei Yang","doi":"10.1016/j.clim.2025.110577","DOIUrl":"10.1016/j.clim.2025.110577","url":null,"abstract":"<div><div>Autoimmune myocarditis refers to the inflammation of myocardial tissue caused by innate and adaptive immune responses, characterized by elevated levels of tumour necrosis factor-α (TNF-α), a classic pro-inflammatory factor. Although hydrogen exhibits anti-inflammatory and antioxidant properties, its therapeutic effects in autoimmune myocarditis have not been evaluated. Therefore, the present study aimed to explore whether hydrogen can alleviate autoimmune myocarditis via TNF-α. An experimental autoimmune myocarditis (EAM) model was established in BALB/c mice via subcutaneous injection of pig-derived myocardial myoglobin emulsified with complete Freund's adjuvant. The treatment group received 2 % hydrogen inhalation twice a day (3 h each time) for 21 days. CD4+ T cell expression was higher in the EAM group than in the Control group, and this increase was attenuated following treatment with hydrogen. Additionally, the levels of TNF-α and related inflammatory factors were substantially higher in the EAM group than in the Control group, and these changes were reversed following hydrogen treatment. Echocardiography assessments demonstrated a significant improvement in heart function following treatment with hydrogen compared to that in the EAM group. Pathological results revealed significant inflammatory cell infiltration and fibrosis in the hearts of the untreated EAM group. Tissue immunofluorescence and protein immunoblotting indicated elevated necroptosis markers in the EAM group, which were downregulated after treatment with hydrogen. This study demonstrates that hydrogen effectively ameliorated autoimmune myocarditis by modulating necroptosis via the TNF/TNFR1 signalling pathway, making it a promising novel therapeutic strategy for myocarditis.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"281 ","pages":"Article 110577"},"PeriodicalIF":3.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144830395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel pathogenic MAN2B2 variants cause systemic lupus erythematosus and dysregulated glycosylation 新型致病性MAN2B2变异引起系统性红斑狼疮和糖基化失调。
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-08-12 DOI: 10.1016/j.clim.2025.110578
Cheng Gong , Changming Zhang , Xu Han , Ying Jin , Yangyang Zhang , Chenlu Liu , Qintao Wang , Jiahui Zhang , Cheng Guo , Qing Zhou , Xiaomin Yu , Zhihong Liu
Genetic factors have been demonstrated to play essential roles in the pathogenesis of systemic lupus erythematosus (SLE). Identifying novel disease-causing genes of SLE helps to reveal its molecular mechanisms and new therapeutic targets. In this study, we identified biallelic loss-of-function variants of MAN2B2 gene in five unrelated SLE patients by whole exome sequencing. They were characterized by autoimmunity, glomerulonephritis, leukopenia, and immune dysregulation. All variants were absent or ultrarare in population databases and predicted to be damaging by multiple in silico tools. Functional study showed that all the identified variants resulted in complete or partial enzymatic activity loss. Analyses of MAN2B2 knockout HEK293T cells, patient-derived induced pluripotent stem cells (iPSCs) and serum samples revealed defects in glycan degradation and N-glycosylation. The patients exhibited enhanced inflammatory signatures, especially the type I interferon and NF-κB pathways. Mechanically, MAN2B2 deficiency leads to dysregulation of unfolded protein response (UPR) upon endoplasmic reticulum stress, resulting in enhanced expression of inflammatory cytokines. Our findings broaden the genetic etiology spectrum of SLE and identify MAN2B2 as a pivotal regulator in maintaining immune homeostasis, paving the way for innovative diagnostic approaches and molecular pathway-specific therapeutic interventions.
遗传因素已被证明在系统性红斑狼疮(SLE)的发病机制中起重要作用。发现新的SLE致病基因有助于揭示其分子机制和新的治疗靶点。在这项研究中,我们通过全外显子组测序在5名不相关的SLE患者中发现了MAN2B2基因的双等位基因功能缺失变异。他们的特点是自身免疫、肾小球肾炎、白细胞减少和免疫失调。所有变异在人口数据库中都不存在或非常罕见,并且被多个计算机工具预测为具有破坏性。功能研究表明,所有确定的变异都导致完全或部分酶活性丧失。对MAN2B2敲除HEK293T细胞、患者来源的诱导多能干细胞(iPSCs)和血清样本的分析显示,多糖降解和n -糖基化存在缺陷。患者表现出增强的炎症特征,特别是I型干扰素和NF-κB途径。机械上,MAN2B2缺乏导致内质网应激时未折叠蛋白反应(UPR)的失调,导致炎症细胞因子的表达增强。我们的研究结果拓宽了SLE的遗传病因谱,并确定了MAN2B2在维持免疫稳态中的关键调节作用,为创新的诊断方法和分子通路特异性治疗干预铺平了道路。
{"title":"Novel pathogenic MAN2B2 variants cause systemic lupus erythematosus and dysregulated glycosylation","authors":"Cheng Gong ,&nbsp;Changming Zhang ,&nbsp;Xu Han ,&nbsp;Ying Jin ,&nbsp;Yangyang Zhang ,&nbsp;Chenlu Liu ,&nbsp;Qintao Wang ,&nbsp;Jiahui Zhang ,&nbsp;Cheng Guo ,&nbsp;Qing Zhou ,&nbsp;Xiaomin Yu ,&nbsp;Zhihong Liu","doi":"10.1016/j.clim.2025.110578","DOIUrl":"10.1016/j.clim.2025.110578","url":null,"abstract":"<div><div>Genetic factors have been demonstrated to play essential roles in the pathogenesis of systemic lupus erythematosus (SLE). Identifying novel disease-causing genes of SLE helps to reveal its molecular mechanisms and new therapeutic targets. In this study, we identified biallelic loss-of-function variants of <em>MAN2B2</em> gene in five unrelated SLE patients by whole exome sequencing. They were characterized by autoimmunity, glomerulonephritis, leukopenia, and immune dysregulation. All variants were absent or ultrarare in population databases and predicted to be damaging by multiple <em>in silico</em> tools. Functional study showed that all the identified variants resulted in complete or partial enzymatic activity loss. Analyses of MAN2B2 knockout HEK293T cells, patient-derived induced pluripotent stem cells (iPSCs) and serum samples revealed defects in glycan degradation and N-glycosylation. The patients exhibited enhanced inflammatory signatures, especially the type I interferon and NF-κB pathways. Mechanically, MAN2B2 deficiency leads to dysregulation of unfolded protein response (UPR) upon endoplasmic reticulum stress, resulting in enhanced expression of inflammatory cytokines. Our findings broaden the genetic etiology spectrum of SLE and identify MAN2B2 as a pivotal regulator in maintaining immune homeostasis, paving the way for innovative diagnostic approaches and molecular pathway-specific therapeutic interventions.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"281 ","pages":"Article 110578"},"PeriodicalIF":3.8,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144854759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation 白细胞介素-5是自体造血干细胞移植的多发性骨髓瘤患者移植综合征的辅助生物标志物。
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-08-05 DOI: 10.1016/j.clim.2025.110575
Xing-Li Zhang , Meng-Meng Pan , Yaroslav Kaminskiy , Shi-Wei Jin , Jian-Qing Mi , Wei-Ping Zhang , Jie Xu
Autologous hematopoietic stem cell transplantation (ASCT) in multiple myeloma (MM) can cause engraftment syndrome (ES), a clinical diagnosis without specific laboratory biomarkers. Herein, six cytokines commonly elevated during transplantation were chronologically detected during ASCT in 96 patients with newly diagnosed MM, 24.0 % of whom experienced ES. Among the molecules demonstrating remarkable peak levels, only IL-5 was able to differentiate ES from non-ES. IL-5 measured on day 12 emerged as an optimal indicator of ES, and its diagnostic value was enhanced when combined with the proportion of endogenous CD8+ T cells after engraftment and daratumumab-naive history. Notably, IL-5 levels on day 6 (IL-5 D6) served as the earliest predictor. 70.8 % of the patients could be predicted as having ES or non-ES via the IL-5 D6 cutoff value and daratumumab treatment history. It suggests that IL-5 can aid in estimating ES, and prior exposure to daratumumab may reduce the incidence of ES.
多发性骨髓瘤(MM)的自体造血干细胞移植(ASCT)可引起植入综合征(ES),这是一种没有特定实验室生物标志物的临床诊断。在此,96例新诊断的MM患者在ASCT期间按时间顺序检测到移植过程中常见的6种细胞因子,其中24.0 %发生ES。在表现出显著峰值水平的分子中,只有IL-5能够区分ES和非ES。第12天测量IL-5是ES的最佳指标,结合移植后内源性CD8+ T细胞比例和daratumumab-naïve病史,IL-5的诊断价值增强。值得注意的是,第6天的IL-5水平(IL-5 D6)是最早的预测因子。70.8% %的患者可通过il - 5d6临界值和达拉单抗治疗史预测为ES或非ES。这表明IL-5可以帮助估计ES,并且先前暴露于达拉单抗可能降低ES的发生率。
{"title":"Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation","authors":"Xing-Li Zhang ,&nbsp;Meng-Meng Pan ,&nbsp;Yaroslav Kaminskiy ,&nbsp;Shi-Wei Jin ,&nbsp;Jian-Qing Mi ,&nbsp;Wei-Ping Zhang ,&nbsp;Jie Xu","doi":"10.1016/j.clim.2025.110575","DOIUrl":"10.1016/j.clim.2025.110575","url":null,"abstract":"<div><div>Autologous hematopoietic stem cell transplantation (ASCT) in multiple myeloma (MM) can cause engraftment syndrome (ES), a clinical diagnosis without specific laboratory biomarkers. Herein, six cytokines commonly elevated during transplantation were chronologically detected during ASCT in 96 patients with newly diagnosed MM, 24.0 % of whom experienced ES. Among the molecules demonstrating remarkable peak levels, only IL-5 was able to differentiate ES from non-ES. IL-5 measured on day 12 emerged as an optimal indicator of ES, and its diagnostic value was enhanced when combined with the proportion of endogenous CD8<sup>+</sup> T cells after engraftment and daratumumab-naive history. Notably, IL-5 levels on day 6 (IL-5 D6) served as the earliest predictor. 70.8 % of the patients could be predicted as having ES or non-ES via the IL-5 D6 cutoff value and daratumumab treatment history. It suggests that IL-5 can aid in estimating ES, and prior exposure to daratumumab may reduce the incidence of ES.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"279 ","pages":"Article 110575"},"PeriodicalIF":3.8,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy 信号淋巴细胞活化分子(SLAM)家族受体在健康和疾病进展中的作用:聚焦于癌症和治疗
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-26 DOI: 10.1016/j.clim.2025.110574
Guhan Luo , Rong Ni , Xuanwei Huang , Yuanhui Li , Dingcun Luo
The SLAM family receptors are immunoglobulin superfamily receptors integral to immune cell communication and regulation. This review consolidates current knowledge on the structures and functions of SLAM family receptors members (SLAMF1–SLAMF9), emphasizing their roles within the tumor microenvironment. Notably, SLAMF7 has been extensively studied in multiple myeloma, serving as both a diagnostic marker and therapeutic target. Other SLAM family receptors are implicated in tumor immune evasion, drug resistance, and T-cell exhaustion. Emerging therapies, including monoclonal antibodies and combinations with immune checkpoint inhibitors, are evaluated. Despite promising findings, challenges such as functional redundancy and an incomplete understanding of the roles of SLAM family receptors across different cancer types persist. Ongoing research into their molecular mechanisms and clinical applications is essential for advancing effective cancer immunotherapies.
SLAM家族受体是免疫球蛋白超家族受体,参与免疫细胞的通讯和调节。本文综述了目前关于SLAM家族受体成员(SLAMF1-SLAMF9)的结构和功能的知识,强调了它们在肿瘤微环境中的作用。值得注意的是,SLAMF7在多发性骨髓瘤中被广泛研究,作为诊断标志物和治疗靶点。其他SLAM家族受体与肿瘤免疫逃避、耐药和t细胞衰竭有关。新兴疗法,包括单克隆抗体和联合免疫检查点抑制剂,进行了评估。尽管有了令人鼓舞的发现,但诸如功能冗余和对SLAM家族受体在不同癌症类型中的作用的不完全理解等挑战仍然存在。对其分子机制和临床应用的持续研究对于推进有效的癌症免疫治疗至关重要。
{"title":"The role of signaling lymphocytic activation molecule (SLAM) family receptors in health and disease progression: Focusing on cancer and therapy","authors":"Guhan Luo ,&nbsp;Rong Ni ,&nbsp;Xuanwei Huang ,&nbsp;Yuanhui Li ,&nbsp;Dingcun Luo","doi":"10.1016/j.clim.2025.110574","DOIUrl":"10.1016/j.clim.2025.110574","url":null,"abstract":"<div><div>The SLAM family receptors are immunoglobulin superfamily receptors integral to immune cell communication and regulation. This review consolidates current knowledge on the structures and functions of SLAM family receptors members (SLAMF1–SLAMF9), emphasizing their roles within the tumor microenvironment. Notably, SLAMF7 has been extensively studied in multiple myeloma, serving as both a diagnostic marker and therapeutic target. Other SLAM family receptors are implicated in tumor immune evasion, drug resistance, and T-cell exhaustion. Emerging therapies, including monoclonal antibodies and combinations with immune checkpoint inhibitors, are evaluated. Despite promising findings, challenges such as functional redundancy and an incomplete understanding of the roles of SLAM family receptors across different cancer types persist. Ongoing research into their molecular mechanisms and clinical applications is essential for advancing effective cancer immunotherapies.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110574"},"PeriodicalIF":3.8,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144723368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of inflammation-driven lung cancer: From external influences to internal regulation 炎症驱动肺癌的机制:从外部影响到内部调节。
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-23 DOI: 10.1016/j.clim.2025.110572
Junhan Wu , Zhe He , Weitao Zhuang , Xin Xia , Zijie Li , Aotian Mo , Yizhang Chen , Rixin Chen , Guibin Qiao
Chronic inflammation is a crucial factor in the development and progression of lung cancer. External factors, such as indoor and outdoor air pollution and occupational hazards, along with imbalances in the lung microbiome, create a pro-inflammatory environment conducive to tumorigenesis. This review explores how various mechanisms drive the production of pro-inflammatory cytokines and immune modulators, leading to a tumor-promoting microenvironment. It also examines the roles of key cells in these processes and highlights the importance of epigenetic modifications in inflammation-driven lung cancer. Understanding these interactions provides insights into targeted therapeutic strategies and underscores the significance of addressing inflammation to reduce lung cancer risk.
慢性炎症是肺癌发生发展的重要因素。外部因素,如室内和室外空气污染和职业危害,以及肺部微生物组的不平衡,创造了有利于肿瘤发生的促炎环境。这篇综述探讨了各种机制如何驱动促炎细胞因子和免疫调节剂的产生,从而导致肿瘤促进微环境。它还检查了关键细胞在这些过程中的作用,并强调了表观遗传修饰在炎症驱动的肺癌中的重要性。了解这些相互作用可以为有针对性的治疗策略提供见解,并强调了解决炎症以降低肺癌风险的重要性。
{"title":"Mechanisms of inflammation-driven lung cancer: From external influences to internal regulation","authors":"Junhan Wu ,&nbsp;Zhe He ,&nbsp;Weitao Zhuang ,&nbsp;Xin Xia ,&nbsp;Zijie Li ,&nbsp;Aotian Mo ,&nbsp;Yizhang Chen ,&nbsp;Rixin Chen ,&nbsp;Guibin Qiao","doi":"10.1016/j.clim.2025.110572","DOIUrl":"10.1016/j.clim.2025.110572","url":null,"abstract":"<div><div>Chronic inflammation is a crucial factor in the development and progression of lung cancer. External factors, such as indoor and outdoor air pollution and occupational hazards, along with imbalances in the lung microbiome, create a pro-inflammatory environment conducive to tumorigenesis. This review explores how various mechanisms drive the production of pro-inflammatory cytokines and immune modulators, leading to a tumor-promoting microenvironment. It also examines the roles of key cells in these processes and highlights the importance of epigenetic modifications in inflammation-driven lung cancer. Understanding these interactions provides insights into targeted therapeutic strategies and underscores the significance of addressing inflammation to reduce lung cancer risk.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"279 ","pages":"Article 110572"},"PeriodicalIF":3.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A specific bone marrow cytokine pattern in de novo acute myeloid leukemia 新发急性髓性白血病的特异性骨髓细胞因子模式
IF 4.5 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-23 DOI: 10.1016/j.clim.2025.110573
Noémie Ravalet , Hélène Guermouche , Pierre Hirsch , Frédéric Picou , Vincent Flament , Caroline Deswarte , Amélie Foucault , Jenny Beaud , Emmanuelle Rault , Emeline Saindoy , Sébastien Lachot , Mara Memoli , Nawa Hachem , Jean-Alain Martignoles , Valérie Gissot , Ludovic Suner , Emmanuel Gyan , Ollivier Legrand , Olivier Hérault , François Delhommeau
Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic cancers. Cytokines play an important role in the regulation of normal and pathologic hematopoiesis. A pro-inflammatory state, described in hematopoietic malignancies, may participate in clonal selection. To identify recurrent cytokine patterns according to AML ontogenic subtypes, we quantified the concentration of 49 cytokines in the bone marrow (BM) plasma from 124 patients with AML or myelodysplastic syndrome (MDS), and from 94 healthy volunteers. We confirmed a pro-inflammatory profile in MDS and AML, with increased concentrations of CXCL8, CXCL10 and IL-6. Only a few cytokines varied when comparing AML to MDS. De novo AML subtypes carry a specific cytokine pattern dominated by the increase in CLEC11A concentrations and the decrease in FLT3 ligand concentrations. These cytokines could participate in clonal selection in this subtype of AML while being less critical in the other AMLs - i.e. secondary-like or TP53-mutated subtypes.
急性髓性白血病(AML)是一种异质性的造血肿瘤。细胞因子在正常和病理造血过程中起着重要的调节作用。在造血恶性肿瘤中描述的促炎状态可能参与克隆选择。为了根据AML的个体成因亚型确定复发性细胞因子的模式,我们量化了124例AML或骨髓增生异常综合征(MDS)患者和94名健康志愿者骨髓(BM)血浆中49种细胞因子的浓度。我们证实了MDS和AML的促炎特征,CXCL8、CXCL10和IL-6的浓度升高。在AML和MDS的比较中,只有少数细胞因子发生变化。新生AML亚型携带一种以CLEC11A浓度升高和FLT3配体浓度降低为主导的特异性细胞因子模式。这些细胞因子可以参与该亚型AML的克隆选择,而在其他AML(即继发性样AML或tp53突变亚型)中则不那么重要。
{"title":"A specific bone marrow cytokine pattern in de novo acute myeloid leukemia","authors":"Noémie Ravalet ,&nbsp;Hélène Guermouche ,&nbsp;Pierre Hirsch ,&nbsp;Frédéric Picou ,&nbsp;Vincent Flament ,&nbsp;Caroline Deswarte ,&nbsp;Amélie Foucault ,&nbsp;Jenny Beaud ,&nbsp;Emmanuelle Rault ,&nbsp;Emeline Saindoy ,&nbsp;Sébastien Lachot ,&nbsp;Mara Memoli ,&nbsp;Nawa Hachem ,&nbsp;Jean-Alain Martignoles ,&nbsp;Valérie Gissot ,&nbsp;Ludovic Suner ,&nbsp;Emmanuel Gyan ,&nbsp;Ollivier Legrand ,&nbsp;Olivier Hérault ,&nbsp;François Delhommeau","doi":"10.1016/j.clim.2025.110573","DOIUrl":"10.1016/j.clim.2025.110573","url":null,"abstract":"<div><div>Acute myeloid leukemia (AML) is a heterogeneous group of hematopoietic cancers. Cytokines play an important role in the regulation of normal and pathologic hematopoiesis. A pro-inflammatory state, described in hematopoietic malignancies, may participate in clonal selection. To identify recurrent cytokine patterns according to AML ontogenic subtypes, we quantified the concentration of 49 cytokines in the bone marrow (BM) plasma from 124 patients with AML or myelodysplastic syndrome (MDS), and from 94 healthy volunteers. We confirmed a pro-inflammatory profile in MDS and AML, with increased concentrations of CXCL8, CXCL10 and IL-6. Only a few cytokines varied when comparing AML to MDS. <em>De novo</em> AML subtypes carry a specific cytokine pattern dominated by the increase in CLEC11A concentrations and the decrease in FLT3 ligand concentrations. These cytokines could participate in clonal selection in this subtype of AML while being less critical in the other AMLs - <em>i.e.</em> secondary-like or <em>TP53-</em>mutated subtypes.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110573"},"PeriodicalIF":4.5,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144712889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mitochondrial bioenergetic failure in SLE immunocytes: Targeting fitness for therapy SLE免疫细胞线粒体生物能量衰竭:靶向适应度治疗
IF 4.5 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-21 DOI: 10.1016/j.clim.2025.110571
Anjali S. Yennemadi , Natasha Jordan , Sophie Diong , Mark Little , Joseph Keane , Gina Leisching

Background

Systemic Lupus Erythematosus (SLE) is characterized by dysregulated immune responses linked to immunometabolic perturbations. While mitochondrial dysfunction has been implicated in SLE, its cell-type-specific impact on immune subsets remains underexplored.

Methods

We repurposed existing RNA-seq data from SLE patient peripheral blood mononuclear cells, with a focus on nuclear-encoded mitochondrial (NEmt) genes, as well as mitochondrial genes themselves, to identify differentially expressed genes compared to healthy controls. Mitochondrial stress tests were performed on freshly isolated CD4+ T cells, CD8+ T cells, B cells, and monocytes from SLE patients and healthy donors to assess bioenergetic function.

Results

RNA-seq revealed that both NEmt genes and mitochondrial genes were downregulated in the PBMC population of SLE patients. In situ mitochondrial stress tests revealed significant reductions in oxygen consumption rate (OCR), indicating impaired oxidative phosphorylation (OXPHOS) across all immune subsets, while extracellular acidification rate (ECAR), a marker of glycolysis, remained unchanged. These findings highlight immune-cell-specific mitochondrial bioenergetic failure in SLE, without compensatory glycolytic adaptation.

Conclusion

Our results position mitochondrial fitness as a novel therapeutic target in SLE. We propose leveraging high-throughput screening of mitochondria-targeted compounds, including FDA-approved agents, to enhance OXPHOS, regulate mitophagy, or mitigate oxidative stress. This precision-based approach offers a paradigm shift from conventional immunosuppression to metabolic recalibration, with the potential to restore immune homeostasis in SLE.
Systemic Lupus Erythematosus (SLE) is characterized by dysregulated immune responses linked to immunometabolic perturbations. While mitochondrial dysfunction has been implicated in SLE, its cell-type-specific impact on immune subsets remains underexplored.Using existing RNA-seq data we focused on nuclear-encoded mitochondrial (NEmt) genes, as well as mitochondrial genes themselves. Mitochondrial stress tests were performed on freshly isolated CD4+ T cells, CD8+ T cells, B cells, and monocytes from SLE patients and healthy donors to assess bioenergetic function.RNA-seq revealed that both NEmt genes and mitochondrial genes were downregulated in the PBMC population of SLE patients. In situ mitochondrial stress tests revealed significant reductions in oxygen consumption rate, indicating impaired oxidative phosphorylation across all immune subsets, while glycolysis remained unchanged. These findings highlight immune-cell-specific bioenergetic failure in SLE and propose mitochondrial fitness as a novel therapeutic target in SLE. This precision-based approach offers a paradigm shift from conventional immunosuppression to metabolic recalibration.
系统性红斑狼疮(SLE)的特点是与免疫代谢紊乱相关的免疫反应失调。虽然线粒体功能障碍与SLE有关,但其对免疫亚群的细胞类型特异性影响仍未得到充分研究。方法:我们重新利用SLE患者外周血单个核细胞的现有RNA-seq数据,重点研究核编码线粒体(NEmt)基因以及线粒体基因本身,以识别与健康对照组相比差异表达的基因。对来自SLE患者和健康供体的新鲜分离的CD4+ T细胞、CD8+ T细胞、B细胞和单核细胞进行线粒体应激测试,以评估生物能量功能。结果rna -seq结果显示,SLE患者PBMC人群中NEmt基因和线粒体基因均下调。原位线粒体应激测试显示氧气消耗率(OCR)显著降低,表明所有免疫亚群的氧化磷酸化(OXPHOS)受损,而细胞外酸化率(ECAR)(糖酵解的标志)保持不变。这些发现突出了SLE中免疫细胞特异性线粒体生物能量衰竭,无代偿性糖酵解适应。结论我们的研究结果表明线粒体适应度是SLE的一个新的治疗靶点。我们建议利用高通量筛选线粒体靶向化合物,包括fda批准的药物,来增强OXPHOS,调节线粒体自噬或减轻氧化应激。这种基于精确的方法提供了从传统免疫抑制到代谢重新校准的范式转变,具有恢复SLE免疫稳态的潜力。系统性红斑狼疮(SLE)的特点是与免疫代谢紊乱相关的免疫反应失调。虽然线粒体功能障碍与SLE有关,但其对免疫亚群的细胞类型特异性影响仍未得到充分研究。利用现有的RNA-seq数据,我们专注于核编码线粒体(NEmt)基因,以及线粒体基因本身。对来自SLE患者和健康供体的新鲜分离的CD4+ T细胞、CD8+ T细胞、B细胞和单核细胞进行线粒体应激测试,以评估生物能量功能。RNA-seq显示,在SLE患者的PBMC人群中,NEmt基因和线粒体基因均下调。原位线粒体应激测试显示氧气消耗率显著降低,表明所有免疫亚群的氧化磷酸化受损,而糖酵解保持不变。这些发现强调了SLE中免疫细胞特异性的生物能量衰竭,并提出线粒体适应性是SLE的一个新的治疗靶点。这种基于精度的方法提供了从传统免疫抑制到代谢重新校准的范式转变。
{"title":"Mitochondrial bioenergetic failure in SLE immunocytes: Targeting fitness for therapy","authors":"Anjali S. Yennemadi ,&nbsp;Natasha Jordan ,&nbsp;Sophie Diong ,&nbsp;Mark Little ,&nbsp;Joseph Keane ,&nbsp;Gina Leisching","doi":"10.1016/j.clim.2025.110571","DOIUrl":"10.1016/j.clim.2025.110571","url":null,"abstract":"<div><h3>Background</h3><div>Systemic Lupus Erythematosus (SLE) is characterized by dysregulated immune responses linked to immunometabolic perturbations. While mitochondrial dysfunction has been implicated in SLE, its cell-type-specific impact on immune subsets remains underexplored.</div></div><div><h3>Methods</h3><div>We repurposed existing RNA-seq data from SLE patient peripheral blood mononuclear cells, with a focus on nuclear-encoded mitochondrial (NEmt) genes, as well as mitochondrial genes themselves, to identify differentially expressed genes compared to healthy controls. Mitochondrial stress tests were performed on freshly isolated CD4+ T cells, CD8+ T cells, B cells, and monocytes from SLE patients and healthy donors to assess bioenergetic function.</div></div><div><h3>Results</h3><div>RNA-seq revealed that both NEmt genes and mitochondrial genes were downregulated in the PBMC population of SLE patients. In situ mitochondrial stress tests revealed significant reductions in oxygen consumption rate (OCR), indicating impaired oxidative phosphorylation (OXPHOS) across all immune subsets, while extracellular acidification rate (ECAR), a marker of glycolysis, remained unchanged. These findings highlight immune-cell-specific mitochondrial bioenergetic failure in SLE, without compensatory glycolytic adaptation.</div></div><div><h3>Conclusion</h3><div>Our results position mitochondrial fitness as a novel therapeutic target in SLE. We propose leveraging high-throughput screening of mitochondria-targeted compounds, including FDA-approved agents, to enhance OXPHOS, regulate mitophagy, or mitigate oxidative stress. This precision-based approach offers a paradigm shift from conventional immunosuppression to metabolic recalibration, with the potential to restore immune homeostasis in SLE.</div><div>Systemic Lupus Erythematosus (SLE) is characterized by dysregulated immune responses linked to immunometabolic perturbations. While mitochondrial dysfunction has been implicated in SLE, its cell-type-specific impact on immune subsets remains underexplored.Using existing RNA-seq data we focused on nuclear-encoded mitochondrial (NEmt) genes, as well as mitochondrial genes themselves. Mitochondrial stress tests were performed on freshly isolated CD4+ T cells, CD8+ T cells, B cells, and monocytes from SLE patients and healthy donors to assess bioenergetic function.RNA-seq revealed that both NEmt genes and mitochondrial genes were downregulated in the PBMC population of SLE patients. In situ mitochondrial stress tests revealed significant reductions in oxygen consumption rate, indicating impaired oxidative phosphorylation across all immune subsets, while glycolysis remained unchanged. These findings highlight immune-cell-specific bioenergetic failure in SLE and propose mitochondrial fitness as a novel therapeutic target in SLE. This precision-based approach offers a paradigm shift from conventional immunosuppression to metabolic recalibration.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110571"},"PeriodicalIF":4.5,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infection risk associated with hypogammaglobulinemia in patients with systemic lupus erythematosus: Real-world evidence from 2014 to 2024 系统性红斑狼疮患者感染风险与低丙种球蛋白血症相关:2014年至2024年的真实世界证据
IF 4.5 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-20 DOI: 10.1016/j.clim.2025.110568
Yang Liu , Sumiao Liu , Ying Liu, Qian Li, Ke Xu

Objectives

To evaluate infection risk associated with hypogammaglobulinemia in patients with systemic lupus erythematosus (SLE).

Methods

We retrospectively analyzed 242 cases of hypogammaglobulinemia identified among 3565 hospitalized SLE patients between 2014 and 2024. Of these, 133 experienced infections, while 109 remained infection-free and served as controls.

Results

Infection rates were comparable among patients with low IgG (60.0 %), IgM (56.3 %) and IgA (57.7 %) levels. Multivariate logistic regression identified low body weight, fever, medication discontinuation, lymphopenia, reduced lymphocyte count, elevated CRP levels, and decreased Th cell and NK cell counts as independent predictors of infection. During follow-up, immunoglobulin levels recovered in most patients, with rates at two years of 76.0 % for IgA, 43.8 % for IgG, and 26.2 % for IgM. Immunoglobulin normalization was associated with reduced infection risk.

Conclusion

Hypogammaglobulinemia increases infection risk in SLE due to multifactorial immune dysfunction. Modifiable clinical and immunologic factors, along with immunoglobulin recovery, may represent actionable targets for intervention.
目的评价系统性红斑狼疮(SLE)患者低丙种球蛋白血症的感染风险。方法回顾性分析2014年至2024年间3565例SLE住院患者中发现的242例低丙种球蛋白血症。其中133人感染,109人未感染,作为对照组。结果低IgG(60.0%)、低IgM(56.3%)、低IgA(57.7%)患者的感染率具有可比性。多因素logistic回归发现,低体重、发烧、停药、淋巴细胞减少、淋巴细胞计数减少、CRP水平升高、Th细胞和NK细胞计数下降是感染的独立预测因素。在随访期间,大多数患者的免疫球蛋白水平恢复,两年内IgA的恢复率为76.0%,IgG的恢复率为43.8%,IgM的恢复率为26.2%。免疫球蛋白正常化与感染风险降低有关。结论多因素免疫功能障碍导致低丙种球蛋白血症增加SLE感染风险。可改变的临床和免疫因素,以及免疫球蛋白恢复,可能是干预的可行目标。
{"title":"Infection risk associated with hypogammaglobulinemia in patients with systemic lupus erythematosus: Real-world evidence from 2014 to 2024","authors":"Yang Liu ,&nbsp;Sumiao Liu ,&nbsp;Ying Liu,&nbsp;Qian Li,&nbsp;Ke Xu","doi":"10.1016/j.clim.2025.110568","DOIUrl":"10.1016/j.clim.2025.110568","url":null,"abstract":"<div><h3>Objectives</h3><div>To evaluate infection risk associated with hypogammaglobulinemia in patients with systemic lupus erythematosus (SLE).</div></div><div><h3>Methods</h3><div>We retrospectively analyzed 242 cases of hypogammaglobulinemia identified among 3565 hospitalized SLE patients between 2014 and 2024. Of these, 133 experienced infections, while 109 remained infection-free and served as controls.</div></div><div><h3>Results</h3><div>Infection rates were comparable among patients with low IgG (60.0 %), IgM (56.3 %) and IgA (57.7 %) levels. Multivariate logistic regression identified low body weight, fever, medication discontinuation, lymphopenia, reduced lymphocyte count, elevated CRP levels, and decreased Th cell and NK cell counts as independent predictors of infection. During follow-up, immunoglobulin levels recovered in most patients, with rates at two years of 76.0 % for IgA, 43.8 % for IgG, and 26.2 % for IgM. Immunoglobulin normalization was associated with reduced infection risk.</div></div><div><h3>Conclusion</h3><div>Hypogammaglobulinemia increases infection risk in SLE due to multifactorial immune dysfunction. Modifiable clinical and immunologic factors, along with immunoglobulin recovery, may represent actionable targets for intervention.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110568"},"PeriodicalIF":4.5,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144686317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iron-dependent cell death: Unlocking Ferroptosis as a key to multiple myeloma therapy 铁依赖性细胞死亡:解锁铁下垂作为多发性骨髓瘤治疗的关键。
IF 3.8 3区 医学 Q2 IMMUNOLOGY Pub Date : 2025-07-16 DOI: 10.1016/j.clim.2025.110570
Fatemeh Karimian , Melika Khademi , Amirsalar Nikkhah Bahrami , Maryam Nabigol , Fatemeh Mikanik , Mehdi Bakhtiyaridovvombaygi , Nader Vazifeh Shiran
Ferroptosis is an iron-dependent cell death characterized by elevated levels of reactive oxygen species (ROS) and the peroxidation of membrane lipids, leading to cellular destruction. This phenomenon results from a disruption in the balance between oxidative and antioxidative processes, with oxidation involving iron and lipid metabolism, and antioxidation primarily relying on GPX4. Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell growth, accounting for 1.3 % of all malignancies. Despite advancements in treatment, MM still has a poor prognosis. Research indicates that malignant MM cells are susceptible to ferroptosis, suggesting that this process may serve as a novel therapeutic strategy to enhance the efficacy of treatment for MM. This review explores current insights into the cellular mechanisms of ferroptosis and its role in eliminating multiple myeloma cells, as well as its effectiveness alongside conventional drugs like Bortezomib.
铁死亡是一种铁依赖性细胞死亡,其特征是活性氧(ROS)水平升高和膜脂过氧化,导致细胞破坏。这种现象是由于氧化和抗氧化过程之间的平衡被破坏,氧化涉及铁和脂质代谢,而抗氧化主要依赖于GPX4。多发性骨髓瘤(Multiple myeloma, MM)是一种以浆细胞生长不受控制为特征的血液系统恶性肿瘤,占所有恶性肿瘤的1.3%。尽管治疗取得了进步,但MM仍然预后不良。研究表明,恶性MM细胞易发生铁凋亡,这表明这一过程可能作为一种新的治疗策略来提高MM的治疗效果。本文探讨了铁凋亡的细胞机制及其在消除多发性骨髓瘤细胞中的作用,以及它与硼替佐米等常规药物的有效性。
{"title":"Iron-dependent cell death: Unlocking Ferroptosis as a key to multiple myeloma therapy","authors":"Fatemeh Karimian ,&nbsp;Melika Khademi ,&nbsp;Amirsalar Nikkhah Bahrami ,&nbsp;Maryam Nabigol ,&nbsp;Fatemeh Mikanik ,&nbsp;Mehdi Bakhtiyaridovvombaygi ,&nbsp;Nader Vazifeh Shiran","doi":"10.1016/j.clim.2025.110570","DOIUrl":"10.1016/j.clim.2025.110570","url":null,"abstract":"<div><div>Ferroptosis is an iron-dependent cell death characterized by elevated levels of reactive oxygen species (ROS) and the peroxidation of membrane lipids, leading to cellular destruction. This phenomenon results from a disruption in the balance between oxidative and antioxidative processes, with oxidation involving iron and lipid metabolism, and antioxidation primarily relying on GPX4. Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell growth, accounting for 1.3 % of all malignancies. Despite advancements in treatment, MM still has a poor prognosis. Research indicates that malignant MM cells are susceptible to ferroptosis, suggesting that this process may serve as a novel therapeutic strategy to enhance the efficacy of treatment for MM. This review explores current insights into the cellular mechanisms of ferroptosis and its role in eliminating multiple myeloma cells, as well as its effectiveness alongside conventional drugs like Bortezomib.</div></div>","PeriodicalId":10392,"journal":{"name":"Clinical immunology","volume":"280 ","pages":"Article 110570"},"PeriodicalIF":3.8,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical immunology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1